An official website of the United States government
Develop and validate translatable biomarkers for their use in preclinical and clinical drug development. These efforts should include the development of pharmacodynamic biomarkers of target engagement, biomarkers of incipient disease (ocular, olfactory) and biomarkers for detection and tracking of synaptic dysfunction.
2030 PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting Progression (R01) RFA-AG-16-014: Alzheimer's Disease Translational Center for Disease Model Resources (U54) PAR-18-519: Sensory and Motor System Changes as Predictors of Preclinical Alzheimer’s Disease (R01) PAR-18-596: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01) NOT-AG-18-001 (#3): in vivo Synaptic Function in Alzheimer's Disease and Related Dementias PAR-19-315: Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional) PAR-22-089: Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional) RFA-AG-24-041: Neural and Non-Neural Mechanisms Underlying Gait as a Preclinical Marker for Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (R01 Clinical Trial Optional) 9.A In Progress Develop and validate translatable biomarkers for their use in preclinical and clinical drug development... DN 2015 AD Summit: 1I and 2I 2018 AD Summit: 3O Workshop: Central and Peripheral Control of Balance held in April 2019 News: Nerve cell biomarker helps predict mortality risk in older-age adults Workshop: Olfactory Dysfunction in Aging and Neurodegenerative Disease Model Organism Development & Evaluation for Late-Onset Alzheimer’s Disease (MODEL-AD) Discovery of Novel Proteomic Targets in Alzheimer’s Disease The IU/JAX Alzheimer’s Disease Precision Models Center: Metabolomics Biomarkers Consortium – Longitudinal Proteomic Changes in CSF from ADNI: Towards Better Defining the Trajectory of Prodromal and Early Alzheimer’s Disease 2016
Develop and validate at least 12 translatable biomarkers for use in preclinical and clinical drug development.
Summary of Key Accomplishments
Through the NIA-supported MODEL-AD Centers, researchers are developing translatable biomarkers that can be used in preclinical and clinical drug development. The Centers are developing new mouse models for late-onset AD and are conducting detailed characterization of the most promising models; this includes a collaboration with the Accelerating Medicines Partnership for AD (AMP AD) focused on comparing the molecular signatures from brain and blood samples between the mouse models of late onset AD and people living with AD.
The key accomplishments summary is current as of July 2022.